Biogen is investing $2 billion in its U.S. manufacturing footprint — but not in Massachusetts, where the drug company is ...

As mothers of children with this disease, we have wept helplessly in recent months as friends — fellow members of a club we ...

A Cambridge-based company developing gene therapies for rare diseases is laying off more than a third of its workforce.

CMS’s Innovation Center plans to expand its workforce as it prepares to launch new health care payment models.

British biopharmaceutical company GlaxoSmithKline will lay off 150 employees in its Cambridge operations by the end of March ...

The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.

Sarepta Therapeutics (SRPT) shares fell as much as 4.8% in premarket trading Monday, poised to extend losses for a second ...

Retail chatter spiked last week as investors piled into three healthcare stocks: GlucoTrack, Sarepta Therapeutics, and TNF ...